28-4180
Sodium succinate dibasic hexahydrate
SAJ first grade, 98.0-102.0%
Synonym(s):
Butanedioic acid disodium salt, Succinic acid disodium salt
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
NaOOCCH2CH2COONa · 6H2O
CAS Number:
Molecular Weight:
270.14
EC Number:
205-778-7
UNSPSC Code:
12352300
PubChem Substance ID:
Beilstein/REAXYS Number:
3921044
MDL number:
Assay:
98.0-102.0%
Grade:
SAJ first grade
Form:
crystalline
grade
SAJ first grade
assay
98.0-102.0%
form
crystalline
availability
available only in Japan
pH
8.0-9.5 (25 °C, 270 g/L)
SMILES string
O.O.O.O.O.O.[Na+].[Na+].[O-]C(=O)CCC([O-])=O
InChI
1S/C4H6O4.2Na.6H2O/c5-3(6)1-2-4(7)8;;;;;;;;/h1-2H2,(H,5,6)(H,7,8);;;6*1H2/q;2*+1;;;;;;/p-2
InChI key
ZBTUYCUNQBRXOR-UHFFFAOYSA-L
Still not finding the right product?
Explore all of our products under Sodium succinate dibasic hexahydrate
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jun Kimura et al.
Cancer science, 104(8), 1083-1090 (2013-05-18)
Pancreatic cancer has a poor prognosis after complete macroscopic resection combined with chemotherapy. Even after neoadjuvant chemotherapy, R0 resection is often not possible. Moreover, current imaging techniques cannot reliably distinguish viable cancer cells from scar tissue at the resectional margin.
Ilya B Zavodnik et al.
Life sciences, 92(23), 1110-1117 (2013-05-07)
The present study was designed for further evaluation of the biochemical mechanism of hepatic mitochondrial dysfunction under oxidative damages induced by organic hydroperoxide, tert-butyl hydroperoxide (tBHP), for estimation of the molecular targets impaired during oxidative stress, and for investigation of
Hiroshi Yoneyama et al.
Anti-cancer drugs, 26(1), 90-100 (2014-09-05)
The efficacy of gemcitabine (GEM), a standard treatment agent for pancreatic cancer, is insufficient because of primary or acquired resistance to this drug. Patients with tumors intrinsically sensitive to GEM gradually acquire resistance and require a shift to second agents